Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
0.9600
-0.0336 (-3.38%)
At close: Mar 28, 2025, 4:00 PM
0.9460
-0.0140 (-1.46%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cardiol Therapeutics stock have an average target of 9.00, with a low estimate of 8.00 and a high estimate of 10. The average target predicts an increase of 837.50% from the current stock price of 0.96.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 24, 2025.
Analyst Ratings
The average analyst rating for Cardiol Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +837.50% | Feb 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +837.50% | Dec 18, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +837.50% | Nov 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +837.50% | Oct 24, 2024 |
Roth MKM | Roth MKM | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +941.67% | Jun 26, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.55
from -0.44
EPS Next Year
-0.51
from -0.55
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 4.7M | |||
Avg | n/a | n/a | 2.3M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.56 | -0.48 | -0.56 | |||
Avg | -0.55 | -0.51 | -0.76 | |||
Low | -0.54 | -0.54 | -0.94 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.